Physician profile
Victor Lawrinenko
NPI 1831134436
$1,176.10
in general payments reported to CMS, 2019-2025
12 companies · $162 in 2025
The $162 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $675 · 2020: $300 · 2021: $12.22 · 2023: $13.59 · 2024: $13.32 · 2025: $162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $188.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $548.36 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $271.45 | 2019-2020 | |
| Pfizer INC. | $87.09 | 2019-2020 | |
| Gilead Sciences, INC. | $46.96 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $46.77 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $40.44 | 2019-2020 | |
| Ucb, INC. | $33.15 | 2020 | |
| Allergan, INC. | $28.73 | 2019 | |
| Boston Scientific Corporation | $25.46 | 2019 | |
| Daiichi Sankyo INC. | $21.88 | 2019 | |
| Medtronic, INC. | $13.59 | 2023 | Manoscan |
| Ambu INC. | $12.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victor Lawrinenko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.